Literature DB >> 1771966

Anthrax vaccines: past, present and future.

P C Turnbull1.   

Abstract

Most livestock vaccines in use throughout the world today for immunization against anthrax are derivatives of the live spore vaccine formulated by Sterne in 1937 and still use descendants of his strain 34F2. Credit belongs to this formulation for effective control in many countries with considerable reduction, sometimes complete elimination, of the disease in animals and, since man generally acquires it from livestock, in man also. However, there are some contraindications of its use and situations in which it cannot be easily administered, and room for development of a successor is discussed. The human vaccines, formulated for at-risk occupations and situations, date from the 1950s (UK vaccine) and 1960s (US vaccine). The rather greater need for improvement of these as compared with the veterinary vaccine stimulated valuable research during the 1980s which has led to a number of promising candidate alternatives for the future.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1771966     DOI: 10.1016/0264-410x(91)90237-z

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  93 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways.

Authors:  William A Langley; Konrad C Bradley; Zhu-Nan Li; Mary Ellen Smith; Matthias J Schnell; David A Steinhauer
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

3.  Identification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation.

Authors:  Indira T Kudva; Robert W Griffin; Jeonifer M Garren; Stephen B Calderwood; Manohar John
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.

Authors:  E D Williamson; I Hodgson; N J Walker; A W Topping; M G Duchars; J M Mott; J Estep; C Lebutt; H C Flick-Smith; H E Jones; H Li; C P Quinn
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule.

Authors:  Zhaochun Chen; Rachel Schneerson; Julie Lovchik; C Rick Lyons; Huaying Zhao; Zhongdong Dai; Joanna Kubler-Kielb; Stephen H Leppla; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

6.  Provider and health care system response to a bioterrorist attack.

Authors:  J D Malone
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-07

7.  Bacillus anthracis Capsular Conjugates Elicit Chimpanzee Polyclonal Antibodies That Protect Mice from Pulmonary Anthrax.

Authors:  Zhaochun Chen; Rachel Schneerson; Julie A Lovchik; Zhongdong Dai; Joanna Kubler-Kielb; Liane Agulto; Stephen H Leppla; Robert H Purcell
Journal:  Clin Vaccine Immunol       Date:  2015-06-03

8.  Anthrax: a continuing concern in the era of bioterrorism.

Authors:  Stefan Riedel
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-07

9.  Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis.

Authors:  Angelo Scorpio; Donald J Chabot; William A Day; David K O'brien; Nicholas J Vietri; Yoshifumi Itoh; Mansour Mohamadzadeh; Arthur M Friedlander
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

10.  Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.

Authors:  Bruce K Brown; Josephine Cox; Anita Gillis; Thomas C VanCott; Mary Marovich; Mark Milazzo; Tanya Santelli Antonille; Lindsay Wieczorek; Kelly T McKee; Karen Metcalfe; Raburn M Mallory; Deborah Birx; Victoria R Polonis; Merlin L Robb
Journal:  PLoS One       Date:  2010-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.